Tenaya Therapeutics CEO Faraz Ali to Speak at Morgan Stanley Global Healthcare Conference on September 9, 2025

Tenaya Therapeutics' CEO to discuss company developments at Morgan Stanley Global Healthcare Conference on September 9, 2025.

Quiver AI Summary

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company focused on developing potentially curative therapies for heart disease, announced that its CEO, Faraz Ali, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 4:50 pm ET. The session will be accessible via a live webcast on Tenaya's website, with an archived replay available for 30 days afterward. Tenaya's pipeline includes innovative gene therapies such as TN-201 for hypertrophic cardiomyopathy and TN-401 for arrhythmogenic right ventricular cardiomyopathy, along with a small molecule treatment, TN-301, for heart failure. The company utilizes advanced technologies for drug development, aiming to address both rare genetic disorders and common heart conditions.

Potential Positives

Tenaya Therapeutics is actively participating in a prestigious healthcare conference, which provides visibility and credibility for the company among investors and industry peers.
The presence of CEO Faraz Ali at the event highlights leadership engagement and commitment to communicating the company's vision and advancements.
The webcast and archived replay of the fireside chat allow broader access to key discussions, potentially attracting new investors and increasing interest in Tenaya’s innovative therapies.
Tenaya's robust pipeline of gene therapies for heart disease positions the company at the forefront of significant medical advancements in the treatment of serious conditions, showcasing its commitment to addressing critical health challenges.

Potential Negatives

None

FAQ

When will Tenaya Therapeutics CEO participate in the Morgan Stanley healthcare conference?

Faraz Ali, Tenaya's CEO, will participate on September 9, 2025, at 4:50 pm ET.

How can I access the webcast of the fireside chat?

The live webcast can be accessed from the Investors section of Tenaya's website.

Will the webcast be available after the live event?

Yes, an archived replay of the webcast will be available for about 30 days after the conference.

What is Tenaya Therapeutics' mission?

Tenaya’s mission is to discover, develop, and deliver potentially curative therapies for heart disease.

What therapies are included in Tenaya's pipeline?

Tenaya's pipeline includes gene therapies for hypertrophic cardiomyopathy (TN-201) and arrhythmogenic right ventricular cardiomyopathy (TN-401).

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$TNYA Insider Trading Activity

$TNYA insiders have traded $TNYA stock on the open market 22 times in the past 6 months. Of those trades, 2 have been purchases and 20 have been sales.

Here’s a breakdown of recent trading of $TNYA stock by insiders over the last 6 months:

DAVID V GOEDDEL purchased 35,714,284 shares for an estimated $24,999,998
GROUP III GP, LP COLUMN purchased 35,714,284 shares for an estimated $24,999,998
FARAZ ALI (Chief Executive Officer) has made 0 purchases and 6 sales selling 27,463 shares for an estimated $24,866.
WHITTEMORE TINGLEY (Chief Medical Officer) has made 0 purchases and 7 sales selling 15,388 shares for an estimated $11,614.
TOMOHIRO HIGA (SVP, Finance) has made 0 purchases and 7 sales selling 6,834 shares for an estimated $5,663.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$TNYA Hedge Fund Activity

We have seen 45 institutional investors add shares of $TNYA stock to their portfolio, and 70 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CASDIN CAPITAL, LLC removed 6,371,002 shares (-94.6%) from their portfolio in Q2 2025, for an estimated $3,893,956
WOODLINE PARTNERS LP removed 5,916,167 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,615,961
BLACKROCK, INC. removed 2,523,802 shares (-48.0%) from their portfolio in Q2 2025, for an estimated $1,542,547
JPMORGAN CHASE & CO removed 2,258,512 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,380,402
VR ADVISER, LLC removed 1,555,556 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $950,755
AQR CAPITAL MANAGEMENT LLC added 966,569 shares (+124.6%) to their portfolio in Q2 2025, for an estimated $590,766
STATE STREET CORP removed 915,431 shares (-81.4%) from their portfolio in Q2 2025, for an estimated $559,511

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$TNYA Analyst Ratings

Wall Street analysts have issued reports on $TNYA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 09/02/2025
Chardan Capital issued a "Buy" rating on 08/07/2025
Canaccord Genuity issued a "Buy" rating on 03/13/2025
Morgan Stanley issued a "Overweight" rating on 03/12/2025

To track analyst ratings and price targets for $TNYA, check out Quiver Quantitative's $TNYA forecast page.

$TNYA Price Targets

Multiple analysts have issued price targets for $TNYA recently. We have seen 4 analysts offer price targets for $TNYA in the last 6 months, with a median target of $5.5.

Here are some recent targets:

Joseph Pantginis from HC Wainwright & Co. set a target price of $5.0 on 09/02/2025
Geulah Livshits from Chardan Capital set a target price of $9.0 on 08/07/2025
Whitney Ijem from Canaccord Genuity set a target price of $6.0 on 03/13/2025
Matthew Harrison from Morgan Stanley set a target price of $5.0 on 03/12/2025

Full Release

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23 ^rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 pm ET.

The live webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website . An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com .

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
[email protected]

Investors
Anne-Marie Fields
Precision AQ
[email protected]